Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention.

@article{Parodi2015MorphineIA,
  title={Morphine is associated with a delayed activity of oral antiplatelet agents in patients with ST-elevation acute myocardial infarction undergoing primary percutaneous coronary intervention.},
  author={Guido Parodi and Benedetta Bellandi and Ioanna Xanthopoulou and Piera Capranzano and Davide Capodanno and Renato Valenti and Katerina Stavrou and Angela Migliorini and David Antoniucci and Corrado Tamburino and Dimitrios Alexopoulos},
  journal={Circulation. Cardiovascular interventions},
  year={2015},
  volume={8 1}
}
BACKGROUND Morphine is recommended in patients with ST-segment-elevation myocardial infarction, including those undergoing primary percutaneous coronary intervention. Suboptimal antiplatelet effect during and after primary percutaneous coronary intervention is associated with increased thrombotic complications. It was hypothesized a potential drug-drug interaction between morphine and antiplatelet agents. We sought to assess platelet inhibition after a loading dose of the currently recommended… CONTINUE READING